TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02222220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: 30 mg/day during 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide
Description: 30 mg/day during 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02322944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality improvement strategies and tools
Description: Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality improvement strategies and tools
Description: Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process optimization
Description: Examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the cath lab, interventional medical team gathering, etc.) and systems (such as pre-paid policy for thrombolysis or PPCI)
Study: NCT01371318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Wound Electronic Medical Record
Description: Online Wound Electronic Medical Record is a medical informatics tool that synthesizes data about complex wound problems from multiple sources and is innovative in its capability to performing these critical tasks: i) identification of the information needed to make treatment decisions at the point of care in real time ii) use intelligent search and report features to identify patients who require emergency interventions, and iii) provide evidence-based clinical decision support to clinicians
Study: NCT01895465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slitted diaper
Description: A diaper where a slit is made through which a urine collection bag is pulled through
Study: NCT02433353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Description: Serotonin norepinephrine reuptake inhibitor

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: EMDR
Description: psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: psychotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Look-alike venlafaxine XR tablets containing no active drug
Study: NCT04075045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellth Smartphone App
Description: Patients will receive the app that provides reminders to adhere to their self-care regimen and ability to track their daily adherence via photos of the self-care related items (medications, blood pressure cuff, meals).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellth Smartphone App
Description: Patients will receive the app that provides reminders to adhere to their self-care regimen and ability to track their daily adherence via photos of the self-care related items (medications, blood pressure cuff, meals).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Incentives
Description: Participants may earn up financial rewards tied to their adherence. The rewards are only usable at pharmacies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Restricted Incentives
Description: Participants may earn up financial rewards tied to their adherence. The rewards are only usable at most stores, except for prohibited purchases such as alcohol, tobacco, or firearms, and is not redeemable for cash.
Study: NCT02312531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B immunoglobulin
Description: Hepatitis B immunoglobulin 200 IU injection at gestational week 20, 24, 28, 32, 34, 36, 38, 39, and 40 in HBIG group mothers.
Study: NCT00802776

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond laser assisted keratoplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PKP
Study: NCT04596462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of SAPHO by PET/CT.
Study: NCT04948385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: deep sedation with propofol +/- adjuvants such as midazolam, sufentanil, lidocaine and/or dehydrobenperidol

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No sedation
Description: No sedation
Study: NCT01057160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rizatriptan
Description: use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rizatriptan
Description: use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
Study: NCT03053193

Intervention type: DIAGNOSTIC_TEST
Intervention: MammaPrint, BluePrint, and Full-Genome Testing
Description: Agendia will run MammaPrint and BluePrint tests using the full genome testing array.
Study: NCT04247594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: synthetic small molecule supplied as 500 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: synthetic small molecule supplied as 500 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: synthetic small molecule supplied as 500 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: synthetic small molecule supplied as 500 mg tablets
Study: NCT03105882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-Spinal Scaffold
Description: Experimental: Neuro-Spinal Scaffold
Study: NCT04281654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Social Conversation
Description: Active Social Conversation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Social Conversation
Description: Active Social Conversation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Social Conversation
Description: Active Social Conversation
Study: NCT03799094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Participants will receive intravenous vitamin C therapy at the indicated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor
Description: Participants will receive Tyrosine kinase inhibitor therapy in cycles: continuous treatment at the indicated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor
Description: Participants will receive Tyrosine kinase inhibitor therapy in cycles: continuous treatment at the indicated dose.
Study: NCT00937599

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brazil Nut
Description: During 16 weeks the adolescents consumed 3-5 nuts/day
Study: NCT02367729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulator
Description: Non-invasive, battery operated neurostimulator of the external ear worn for 5 days each week x 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Inactive neurostimulator device pre-programmed to be inactive. To be worn for 5 days each week x 4 weeks.
Study: NCT02421107

Intervention type: OTHER
Group type: OTHER
Intervention: Glysure CGM

Intervention type: OTHER
Group type: OTHER
Intervention: iStat intermittent testing
Study: NCT04265456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 100mg
Description: Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 100mg
Description: Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1300mg
Description: Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1300mg
Description: Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
Study: NCT02726373

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: type of walking
Description: Subjects walked either intermittently or continuously twice a week for 4 weeks, then crossed over

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: type of walking
Description: Subjects walked either intermittently or continuously twice a week for 4 weeks, then crossed over
Study: NCT02009982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation
Description: Catheter Ablation of Vagal Inputs in Left Atrium

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
Description: This is the device that will be used to perform the Cardioneuroablation procedure
Study: NCT01891786

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management Intervention
Description: The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management Intervention
Description: The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk Result
Description: Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.
Study: NCT02953262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My HealtheVet Brochure
Description: Participants will receive a mailed brochure with basic My HealtheVet content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My HealtheVet Brochure
Description: Participants will receive a mailed brochure with basic My HealtheVet content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My HealtheVet Training Guide for Veterans Living with Diabetes
Description: Participants will be mailed a bound My HealtheVet training guide with step by step instructions on how to register, upgrade to Premium account, refill prescriptions, use secure messaging, download their Blue Button reports, and other features

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My HealtheVet Training Guide for Veterans Living with Diabetes
Description: Participants will be mailed a bound My HealtheVet training guide with step by step instructions on how to register, upgrade to Premium account, refill prescriptions, use secure messaging, download their Blue Button reports, and other features

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My HealtheVet Training Guide for Veterans Living with Diabetes
Description: Participants will be mailed a bound My HealtheVet training guide with step by step instructions on how to register, upgrade to Premium account, refill prescriptions, use secure messaging, download their Blue Button reports, and other features

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: My HealtheVet Group Training
Description: Participants will be invited to participate in a scheduled group training to learn how to use My HealtheVet to help manage their diabetes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My HealtheVet Group Training
Description: Participants will be invited to participate in a scheduled group training to learn how to use My HealtheVet to help manage their diabetes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My HealtheVet Group Training
Description: Participants will be invited to participate in a scheduled group training to learn how to use My HealtheVet to help manage their diabetes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My HealtheVet Group Training
Description: Participants will be invited to participate in a scheduled group training to learn how to use My HealtheVet to help manage their diabetes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My HealtheVet Individual Training
Description: Participants will be invited to participate in a one-on-one training to learn how to use My HealtheVet to help manage their diabetes at a time of their convenience.
Study: NCT01432782

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline 4 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline
Study: NCT00666718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: patient glucose-level dependent, injection, once daily in the evening, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Protamine Suspension (ILPS)
Description: patient glucose-level dependent, injection, once daily in the evening, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: subcutaneous injections prior to meals, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: subcutaneous injections prior to meals, 24 weeks
Study: NCT01863095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback and Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Feedback and Exercise
Study: NCT00159081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol, Risperidone (drug)
Description: targeted dose of 2-4 mg/day over 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol, Risperidone (drug)
Description: targeted dose of 2-4 mg/day over 1 year
Study: NCT02935946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Liquid Barium
Description: Cold Liquid is defined as being between 4-9 °C. One liter bottles of Poland Spring Natural Spring Water will be kept in the radiology suite to remain at room temperature. As described by Fink and colleagues,(42) the bottled water will be used to mix the barium powder to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula. After the barium is prepared, 2oz will be poured into a bottle and placed in a refrigerator set to 36°F; this will allow the barium to cool to approximately 4-9°C. Before oral administration, the barium mixture will be measured with a thermometer (TP3001 Digital Thermometer from Red Lantern®) to document the exact temperature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Liquid Barium
Description: Cold Liquid is defined as being between 4-9 °C. One liter bottles of Poland Spring Natural Spring Water will be kept in the radiology suite to remain at room temperature. As described by Fink and colleagues,(42) the bottled water will be used to mix the barium powder to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula. After the barium is prepared, 2oz will be poured into a bottle and placed in a refrigerator set to 36°F; this will allow the barium to cool to approximately 4-9°C. Before oral administration, the barium mixture will be measured with a thermometer (TP3001 Digital Thermometer from Red Lantern®) to document the exact temperature.
Study: NCT00872365

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Regular aerobic physical exercise
Description: Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Regular aerobic physical exercise
Description: Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Micronutrients
Description: Zinc 30mg, Magnesium 400mg, Beta-carotene 9 mg, Tocopherol 30mg, vitamin C 200mg y Niacin 100mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Micronutrients
Description: Zinc 30mg, Magnesium 400mg, Beta-carotene 9 mg, Tocopherol 30mg, vitamin C 200mg y Niacin 100mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Activities of daily living + placebo
Description: Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist and prenatal care.~Placebo Comparator: Equivalent to placebo (maltodextrin).
Study: NCT00776269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: argon laser and radiofrequency
Study: NCT03719261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chitosan nanoparticles
Description: Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hypochlorite
Description: Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
Study: NCT01039584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butoconazole Nitrate Vaginal Cream
Description: vaginal cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vaginal cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gynazole 1 vaginal cream
Description: vaginal cream
Study: NCT04156282

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: knot burial technique
Description: surgical suturing intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classical closure
Description: surgical suturing intervention
Study: NCT03990246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acid stable emulsion with solid droplets
Description: This will be a 250 mL acid stable beverage emulsion in which the droplets are crystalline. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.2% of the emulsifier sorbitan monooleate (Tween80)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acid stable emulsion with liquid droplets
Description: This will be a 250 mL acid stable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.2% of the emulsifier sorbitan monooleate (Tween80)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acid unstable emulsion with solid droplets
Description: This will be a 250 mL acid unstable beverage emulsion in which the droplets are solid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.5% of the emulsifier sorbitan monostearate (Span60)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acid unstable emulsion with liquid droplets
Description: This will be a 250 mL acid unstable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.5% of the emulsifier sorbitan monostearate (Span60)